Black Diamond Therapeutics, Inc. Common Stock
BDTXBlack Diamond Therapeutics, Inc. (BDTX) is a biotechnology company focused on developing precision oncology medicines. It utilizes its unique oncology master key platform to identify and target specific genetic mutations in cancer, aiming to deliver personalized treatment options for patients with difficult-to-treat tumors.
Company News
Black Diamond Therapeutics reported a narrower net loss in Q2 2025, with improved operational efficiency and focus on silevertinib clinical development. The company completed Phase 2 trial enrollment and maintains a cash runway through Q4 2027.
Clarus reported Q2 2025 earnings with mixed results, narrowly beating analyst expectations on revenue and adjusted net loss per share, but experiencing revenue decline and ongoing profitability challenges.
Servier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.
The BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies.
Black Diamond Therapeutics reported encouraging initial Phase 2 data for BDTX-1535 in patients with recurrent EGFR-mutant NSCLC. The company also presented real-world data on treatment practices and outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations. Black Diamond expects to provide clinical updates and regulatory feedb...
